ReviewJournal of surgical oncology2011
Translational/personalized medicine, pharmaco/surgico/radiogenomics, lymphatic spread of cancer, and medical ignoromes.
Review in Journal of surgical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Multimodality image fusion-guided procedures: technique, accuracy, and applications.Cardiovascular and interventional radiology · 2012Review
- Biomarkers of cancer metastasis through the lymphovascular system: future perspectives.Clinical & experimental metastasis · 2012Article
- Cone-beam computed tomography fusion and navigation for real-time positron emission tomography-guided biopsies and ablations: a feasibility study.Journal of vascular and interventional radiology : JVIR · 2012Article
- Chinese integrative medicine: translation toward person-centered and balanced medicine.Chinese journal of integrative medicine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
In the elusive quest for "personalized" cancer treatments based on pharmacogenomics, diverse challenges must be overcome: questionable validity of "molecular models of life," obstacles to bidirectional translation of scientific advances from bench to bedside to community, and limitations of bioinformatics to recognize and deal with "ignoramics/ignoromes" (expanding unknowns in cancer biology, theranostics, and therapeutic choices). These considerations apply to lymphatic system functioning-lymphatic vessels, lymph, lymph nodes, and lymphocytes-in diseases like cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.